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von Hippel–Lindau protein
p300HIF-1α plays a central role in cellular adaptation to hypoxia, and is closely related to the pathogeneses of life-
threatening disorders. HIF-1α induces the expressions of numerous hypoxia-induced genes through two
transactivation domains; N-terminal TAD (NAD) and C-terminal TAD (CAD). Furthermore, p300 is known
to boost CAD-dependent transactivation, and CBP/p300-interacting transactivator with an ED-rich tail 2
(CITED2) inhibits HIF-1α-driven gene expression by interfering with the interaction between CAD and
p300. However, few researches have focused on the role of CITED2 in the regulation of NAD activity, and
thus, we addressed this point. CITED2 was found to attenuate the hypoxic activations of NAD-dependent
and CAD-dependent genes, suggesting that CITED2 negatively regulates both CAD and NAD. Immunoprecip-
itation analyses showed that NAD interacts with the Cystein/Histidine region (CH) 1 and CH3 domains of
p300. Moreover, CH1 and CH3 both were required for NAD-dependent transactivation. Furthermore,
CITED2 was found to inactivate NAD by interfering with NAD binding to CH1, but not to CH3. These results
indicate that CITED2 inactivates HIF-1α by blocking p300 recruitment by both NAD and CAD. We also
found that pVHL inhibits NAD activity regardless of NAD degradation by blocking the interaction between
p300 and NAD. Summarizing, NAD was activated by binding to p300, and this was blocked by either
CITED2 or pVHL. We propose that pVHL controls NAD during normoxia and that CITED2 controls NAD during
hypoxia. Our results provide a new strategy for controlling HIF-1α.CITED2, CBP/p300-interacting
g HIF; VHL, von Hippel–Lindau;
inal transactivation domain;
82 2 745 7996.
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To adapt to hypoxia, mammalian cells induce numerous proteins
required for erythrogenesis, angiogenesis, and anaerobic energy
metabolism. HIF-1 plays a central role in cellular adaptation to hypox-
ia [1], and a growing body of evidence supports that HIF-1 is closely
related to the pathogeneses of life-threatening disorders, such as,
neoplasm, ischemia, inﬂammation, and anemia [2,3]. HIF-1 is a het-
erodimeric transcription factor consisting of HIF-1α and HIF-1β
(also called ARNT), both of which belong to the basic helix-loop-
helix (bHLH) Per-ARNT-Sim (PAS) family [4]. Of two subunits, HIF-
1α is oxygen-dependently regulated at the post-translational level,
via its oxygen-dependent degradation domain (ODDD). HIF-1α
ODDD is hydroxylated by prolyl hydroxylases (PHDs), then ubiquiti-
nated by pVHL, and ﬁnally degraded by proteasomes. Because oxygenis required for the hydroxylation process, HIF-1α is stabilized during
hypoxia [5,6].
HIF-1α has two transactivation domains (TADs), namely, N-termi-
nal TAD (NAD) and C-terminal TAD (CAD). Several authors have
pointed out that the TADs have different roles in hypoxic responses
by transactivating distinct gene subsets [7]. Based on the responsive-
ness to factor inhibiting HIF (FIH; a CAD-speciﬁc inhibitor), Dayan et
al. identiﬁed the genes governed by CAD and by NAD [8]. For example,
CA9, EPO and VEGF were found to be transcribed by CAD, but PGK1,
Eno1, and BNIP3 by NAD. To understand HIF-1-driven gene regula-
tion, we need to investigate how CAD and NAD are regulated by oxy-
gen, but only CAD has been extensively investigated to date.
p300/CBP functions as a critical coactivator during HIF-driven
transcription. Brieﬂy, p300/CBP remodels chromatin architecture by
acetylating histones, which allows transcriptional regulators to ap-
proach DNA [9]. CAD recruits p300/CBP by directly binding to the
CH1 domain of p300/CBP. This interaction occurs exclusively under
hypoxia because the FIH-mediated Asn803 hydroxylation interferes
with the CAD–CH1 interaction under normoxia [10]. In contrast to
CAD, the molecular mechanism whereby NAD is regulated is poorly
understood. Recently, Poellinger and his colleagues showed that
NAD and CAD require CBP for transcriptional activation and that
NAD recruits CBP by binding to CH3, rather than to CH1 [11]. Given
Table 1
Nucleotide sequences of primers used in RT-PCR.
Targets Forward primers (5′ to 3′) Reverse primers (5′ to 3′)
CA9 TATGAGGGGTCTCTGACTACA TTCTCATCTGCACAAGGAAC
EPO AACAATCACTGCTGACACTT AGAGTTGCTCTCTGGACAGT
VEGF AACTTTCTGCTGTCTTGG TTTGGTCTGCATTCACAT
PGK1 GAGCTTCACTTTCCAAGCTA AACAGGCAAGGTAATCTTCA
ENO1 GAGCTGCTGAAGACTGCTAT TCTGAGGAGCTGGTTGTACT
BNIP3 GATACCCATAGCATTGGAGA CTAAATTAGGAACGCAGCAT
HIF-1α CCCAGATTCAGGATCAGACA ACCATCATGTTCCATTTTTCG
HIF-2α TCATCATGTGTGAACCAATC GAACACCACGTCATTCTTCT
GAPDH TGTGGTCATGAGTCCTTCCA CGAGATCCCTCCAAAATCAA
β-actin AAGAGAGGCATCCTCACCCT ATCTCTTGCTCGAAGTCCAG
A
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transcriptional activity by being recruited by either CAD or NAD.
CBP/p300 interacting transactivator with an ED-rich tail 2
(CITED2; also called Mrg1 or p35srj) is a transcriptional co-regulator
that binds to the CH1 of p300/CBP [12]. It functions as a positive or
negative regulator of gene expression, depending on its target pro-
teins. When CITED2 associates with AP-2, it acts as a coactivator by
enhancing p300/CBP recruitment to AP-2 [13]. In contrast, CITED2
acts as a negative regulator of the HIF-1 signaling. Mechanistically,
CITED2 blocks the HIF-1α binding to p300/CBP by competing for
CH1 binding, and by so doing functionally represses HIF-1 activity
[14]. Interestingly, since CITED2 is substantially induced during
hypoxia, it is believed to balance HIF activity in a negative feedback
manner. Theoretically, to carry out such a function, CITED2 might
control both TADs of HIF-1α. However, studies on CITED2 have
focused on its inhibition of CAD, and it has not been determined
whether CITED2 regulates NAD activity. Given a recent reportFig. 1. CITED2 negatively regulates both CAD- and NAD-dependent genes during hypox-
ia. Hep3B cells were transfected with 3 μg of pcDNA or pc-CITED2 plasmid or 100 nM of
si-control or si-CITED2. After transfected with plasmid or siRNA, cells were incubated
under normoxic or hypoxic conditions for 16 h. RNAs were reverse-transcribed,
cDNAs were ampliﬁed over 17 to 22 cycles with 32P-labeled dCTP, and the products
were electrophoresed on a 4% polyacrylamide gel and autoradiographed.showing that NAD, like CAD, recruits p300/CBP [11], we addressed
the possibility that CITED2 regulates NAD-dependent gene regulation.
2. Materials and methods
2.1. Reagents and antibodies
Culture media were purchased from Invitrogen (Carlsbad, CA),
and fetal calf serum from Sigma-Aldrich (St. Louis, MO). [α-32P]CTP
(500 Ci/mmol) was obtained from NEN Life Science (Boston, MA).
Anti-HIF-1α antibody was raised in rabbits against human HIF-1α
[15]. CITED2, p300, FIH, β-tubulin, Gal4(DBD), and VP16(TAD) prima-
ry antibodies and HRP-conjugated secondary antibodies were pur-
chased from SantaCruz Biotechnology(Santa Cruz, CA); anti-HA-tag
antibody from Sigma-Aldrich.
2.2. Cell culture
HEK293T (human embryonic kidney), MCF7 (human breast can-
cer), and Hep3B (human hepatoma) cell-lines were obtained from
American Type Culture Collection (Manassas, VA), and VHL(+/+;
−/−) RCC4 (renal cell carcinoma) from the European Collection of
Cell Cultures (London). Cells were cultured in Dulbecco's modiﬁedB
Fig. 2. CITED2 represses the transcriptional activities of CAD and NAD. (A) pcDNA
or CITED2 plasmid (1 μg) was co-transfected with the Gal4-CAD plasmid (500 ng),
Gal4-NAD plasmid (1 μg) and 100 or 500 ng of the Gal4-luc reporter plasmid into
HEK293T or Hep3B cells, respectively. After cells were incubated under normoxic or
hypoxic conditions for 16 h, luciferase activity was measured by a luminometer. Results
(means±SDs, n=4) are presented as relative activities versus the normoxic control.
(B) siRNAs (100 nM) were co-transfected with indicated plasmids into HEK293T or
Hep3B cells. After stabilized for 24 h, the cells were incubated under normoxic or hyp-
oxic conditions for 16 h. Luciferase activities (means±SDs, n=4) were normalized to
β-gal activities and presented as relative values versus the normoxic activity. * and #
denote pb0.05 versus the normoxic control and the hypoxic control, respectively.
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10% heat-inactivated fetal calf serum. Gas tensions in the O2/CO2
incubator were 20% O2/5% CO2 for normoxic incubation or 1% O2/5%
CO2 for hypoxic incubation.
2.3. Preparation of plasmids, siRNAs and transfection
Hemagglutinin (HA)-tagged HIF-1α, HA-tagged p300, Gal4-CAD
(aa. 776–826 of HIF-1α), Gal4-NAD (aa. 498–603 of HIF-1α), Gal4-
NAD P564A mutant, Gal4-NAD L574S mutant, VP16-p300 CH1, and
VP16-p300 CH3 plasmids were constructed, as previously described
[16]. CITED2 (GenBank ID: NM_006079) plasmid and siRNAwere con-
structed as previously described [17]. The sequences of CITED2 and
control siRNAs used are 5′-UGACGGACUUCGUGUGCAATT -3′ and 5′-
AUGAACGUGAAUUGCUCAATT-3′, respectively. For transient transfec-
tion with plasmids or siRNAs, 40% conﬂuent cells in 60-mm dishes
were transfected with plasmids or siRNAs using calcium phosphate
or Lipofectamine reagent (Invitrogen). The transfected cells were
allowed to be stabilized for 40 h before being used in experiments.
2.4. Reporter and mammalian two-hybrid assays
To examine NAD and CAD activities, Hep3B, MCF7 and HEK293T
cells were co-transfected with Gal4-promoter luciferase, Gal4-CAD/
NAD, CITED2, or/and CITED2 siRNA using calcium phosphate or Lipo-
fectamine reagent. To examine the interaction between NAD/CAD
and p300, HEK293T cells were cotransfected with Gal4-luciferaseA
B C
Fig. 3. CITED2 negatively regulates NAD irrespective of protein stability. (A) Gal4-NAD (aa. 4
with Gal4-Luc reporter and β-gal plasmids into HEK293T cells. After stabilized for 24 h, the c
(means±SDs, n=4) were normalized to β-gal activities and presented as relative values
(100 nM) was co-transfected with one of Gal4-NAD mutants, Gal4-Luciferase reporter and β
conditions for 16 h. Results (means±SDs, n=4) are presented as relative values versus the
induction folds between two groups.reporter, Gal4-NAD/CAD, and VP16-CH1/CH3 plasmids. The CMV-β-
gal plasmid was included in all cotransfection sets. The ﬁnal DNA
or siRNA concentrations were adjusted by adding pcDNA or control
siRNA. After 40 h of stabilization, transfected cells were incubated
under normoxic or hypoxic conditions for 16 h, and then lysed to
determine luciferase. β-gal activities were measured to normalize
transfection efﬁciencies.
2.5. Immunoblotting and immunoprecipitation
Cell lysates were separated on 6.5–12% sodium dodecylsulfate
(SDS)/polyacrylamide gels, and transferred to an Immobilon-P mem-
brane (Millipore, Bedford, MA). Membranes were blocked with 5%
skimmilk for 1 h and then incubated overnight at 4 °C with a primary
antibody (1:1000). Membranes were incubated with a horseradish
peroxidase-conjugated secondary antibody (1:5000) for 1 h, and
stained using the ECL Plus kit (Amersham Biosciences, Piscataway,
NJ). To analyze protein interactions, cell lysates were incubated
with anti-Gal4 or anti-p300 overnight at 4 °C, and the immune com-
plexes were precipitated with protein A/G beads (Santa Cruz, CA)
for 4 h. The precipitated proteins were eluted in the denaturing
SDS sample buffer and subjected to SDS-PAGE and immunoblotting.
2.6. Semiquantitative RT-PCR
mRNA levels were quantiﬁed using a highly sensitive semi-
quantitative RT-PCR. Total RNAs, extracted using TRIZOL (Invitrogen),98–603 of HIF-1α), Gal4-NAD_P564A, or Gal4-NAD_L574S plasmid was co-transfected
ells were incubated under normoxic or hypoxic conditions for 16 h. Luciferase activities
versus the normoxic activity of wild-type Gal4-NAD. (B–C) CITED (1 μg) or si-CITED2
-gal plasmid into HEK293T cells. The cells were incubated under normoxia or hypoxic
normoxic controls. * denotes pb0.05 between indicated groups and x-numbers present
AB
Fig. 4. CITED2 interferes with p300 binding to NAD under hypoxia. p300 binding to
NAD was examined using immunoprecipitation and immunoblotting analyses.
(A) Gal4-NAD plasmid was co-transfected with HA-p300 into HEK293T cell. On 24 h
after transfection, cells were incubated under hypoxic conditions or treated with
130 μM desferrioxamine (DFO) for 8 h. Cell extracts were immunoprecipitated with
anti-HA afﬁnity gel for 4 h, and coprecipitated Gal4-NAD was analyzed using anti-
Gal4 antibody. (B) HEK293T cells were co-transfected with Gal4-NAD, and HA-p300
and CITED2 (1, 2, and 4 μg). The interaction between Gal4-NAD and p300 was analyzed
by immunoprecipitation and immunoblotting. Each protein amount was estimated
using the ImageJ program (NIH, USA), and the ratio of co-precipitated Gal4-NAD to
its input was calculated (% of Input).
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pliﬁed over 15–22 PCR cycles (95 °C for 20 s, 50 °C for 30 s, and 70 °C for
1 min) in a 20 μl of reaction mixture containing 5 μCi of [α-32P]dCTP.
The PCR products were electrophoresed on a 4% polyacrylamide gel,
and dried gels were autoradiographed. PCR primers were designed as
shown in Table 1.
2.7. Data analyses
Reporter data were obtained from four independent experiments
and analyzed using Microsoft Excel 2007 software. The results were
expressed as means and standard deviations, and statistically analyzed
by two-sided Mann–Whitney U test. Signiﬁcant differences between
groups were considered when p value was less than 0.05. Immuno-
blotting, immunoprecipitation, and RT-PCR analyses were performed
three times, and representative data were shown in ﬁgures.
3. Results
3.1. CITED2 represses either CAD- or NAD-dependent genes during
hypoxia
Hep3B cells transfected with CITED2 plasmid or siRNA, were incu-
bated under normoxic or hypoxic conditions for 16 h. Although cell
numbers were somehow reduced after hypoxic incubation, the manip-
ulations of CITED2 expression did not affect cell viability (Fig. S1.A). As
previously reported [8], we classiﬁedHIF-1 target genes into two groups
of CAD- and NAD-dependent genes and analyzed their mRNA levels
using a highly sensitive semiquantitative RT-PCR technique. The hypox-
ic expressions of CAD-dependent genes (CA9, EPO and VEGF) were
repressed by CITED2 overexpression and enhanced by CITED2 knock-
down. Likewise, NAD-dependent genes (PGK1, ENO1 and BNIP3) were
also negatively regulated by CITED2 (Fig. 1). We also conﬁrmed that
two house-keeping genes, HIF-1/2α and FIH are constantly expressed
regardless of CITED2 overexpression or knock-down. To rule out the tar-
get-off effect of CITED2 siRNA,we treatedHep3B cellswith other siRNAs
at two concentrations (20 nM and 100 nM). These siRNAs also showed
good CITED2-silencing effects and enhanced the hypoxic inductions
of both CAD- and NAD-dependent genes (Fig. S1.B). These ﬁndings sup-
port our hypothesis that NAD activity is also controlled by CITED2.
3.2. CITED2 represses the transcriptional activities of CAD and NAD
To conﬁrm the effects of CITED2 on HIF-1α TADs, we analyzed the
activities of Gal4-CAD and Gal4-NAD reporters. Hep3B, MCF7 and
HEK293T cells were transfected with CITED2 plasmid or siRNA. We
found that the activities of both reporters were signiﬁcantly inhibited
by CITED2 overexpression (Fig. 2.A). To examine whether CITED2
controls TAD activities endogenously, we examined the effects of
CITED2 siRNA on CAD and NAD activities, and found that both CAD
and NAD are noticeably activated by CITED2 knock-down (Fig. 2.B).
In these samples, ectopic expression and knock-down of CITED2
were conﬁrmed by checking CITED2 protein levels. Moreover, ectopic
expressions of Gal4-CAD and Gal4-NAD were neither signiﬁcantly
altered during hypoxia, nor by CITED2 plasmid or siRNA (Fig. S2).
To conﬁrm the NAD control by CITED2, we checked if CITED2 plasmid
and siRNA regulate NAD activity in a dose-dependent manner, and
found their dose-dependent effects on NAD activity (Fig. S3). These
results indicate that CITED2 negatively regulates both TADs.
3.3. CITED2 inactivates NAD at a step after the prolyl-hydroxylation of
NAD
NAD at the C-terminal part of ODDD includes a Pro564 residue
that is targeted by PHDs. Indeed, To and Huang demonstrated that
PHD2 binds to NAD and by so doing, represses the transcriptionalactivity of NAD [16]. To examine whether NAD inactivation by
CITED2 is not attributed to the action of PHD, we analyzed the activ-
ities of NAD/P564A and NAD/L574S, both of which are not targeted by
PHDs. As was expected, both mutants were constitutively active even
in normoxia and were slightly activated in hypoxia (Fig. 3.A). Further-
more, both mutants were inactivated by CITED2 overexpression
(Fig. 3.B), and more activated by CITED2 knock-down (Fig. 3.C). In
the samples, the expression or knock-down of Gal4-NADs or CITED2
was veriﬁed by checking the levels of these proteins (Fig. S4). These
results indicate that CITED2 repressed NAD activity at a step after
PHD targets NAD.
3.4. CITED2 competes with NAD for p300 binding
CAD recruits p300 at its target genes and this boosts CAD-driven
transcription [18]. To examine whether NAD also recruits p300, we
co-expressed HA-p300 and Gal4-NAD in HEK293T cells. NAD was
found to associate with p300 under hypoxic or desferrioxamine-trea-
ted condition, but not under normoxia (Fig. 4.A). Given that the input
levels of Gal4-NAD were not altered substantially, the hypoxic bind-
ing of NAD-p300 is unlikely to be due to increased expression of
Gal4-NAD. We also found that CITED2 attenuates NAD binding to
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these results suggest that NAD and CAD interact with p300 indepen-
dently and that CITED2 inhibits both interactions.
3.5. NAD binds to both CH1 and CH3 of p300
To examine which one, of CH1 and CH3, binds to NAD, we checked
protein interactions using a HIF-1αmutant lacking NAD or CAD (des-
ignated HIF△NAD and HIF△CAD, respectively). Consequently, CH1
coprecipitated with HIF-1α, HIF△NAD, and HIF△CAD (Fig. 5.A). How-
ever, CH3 did not associate with HIF△NAD, while it did with HIF-1α
and HIF△CAD (Fig. 5.B). We rechecked NAD–CHs interactions using
the minimal domain of NAD, and found that CH1 and CH3 both asso-
ciates with NAD (Fig. 5.C). To recheck the interactions, we examined
which CH domain competes with p300 for NAD binding. As expected,
CH1 and CH3 both inhibited p300 binding to NAD (Fig. 5.D). These
results constantly indicate that NAD interacts with p300 by simulta-
neously binding to CH1 and CH3. In addition, given that NAD–p300
complex was dissociated by either CH1 or CH3, two CH domains are
likely to tighten the NAD–p300 interaction cooperatively.
3.6. CITED2 inactivates NAD by interfering with the NAD–CH1
interaction
To check NAD–CHs interactions functionally, we performed mam-
malian two-hybrid assays. Gal4-NAD was activated in hypoxia, and
this activity was signiﬁcantly stimulated by both VP16-CH1 and
VP16-CH3 (Fig. 6.A). This result further supports the notion that
NAD interacts with CH1 and CH3. Using this system, we investigatedA
C
Fig. 5. NAD interacts with p300 through its binding to both CH1 and CH3. (A–B) HEK293T cel
HIF-1α△CAD (lacking aa. 781–826), and VP16-CH1 or VP16-CH3. After stabilized for 24 h,
cipitated with anti-HA afﬁnity beads, and coprecipitated VP16-CH1 and -CH3 were analyze
CH3 and incubated under hypoxic conditions for 8 h. Cell extracts were prepared and im
using anti-VP16. (D) Indicated plasmids were co-transfected into HEK293T cells and incuba
precipitation and immunoblotting.how CITED2 represses NAD activity. The CH1-dependent activity of
NAD was noticeably attenuated by CITED2 in both normoxic and hyp-
oxic conditions (Fig. 6.B, left), whereas in contrast, CH3-dependent
activity remained high and was further induced in hypoxia even
after CITED2 overexpression (Fig. 6.B, right). In the samples, the levels
of expressed proteins were veriﬁed by immunoblotting (Fig. S5).
These ﬁndings show that CITED2 represses NAD activity by speciﬁcal-
ly interfering with NAD–CH1 binding, but not with NAD–CH3 bind-
ing. Given that CH1 and CH3 both are required for the interaction
between p300 and NAD, CITED2 blockage of the NAD–CH1 interaction
may be sufﬁcient to dissociate p300 from NAD.
3.7. pVHL functionally inhibits NAD
CITED2 is induced during hypoxia and functions to set back NAD-
and CAD-dependent transcriptions by binding CH1. Therefore, CITED2
might not play a central role in controlling HIF-1α during normoxia.
The oxygen-dependent regulation of HIF-1 activity is mainly due
to the oxygen-dependent degradation of HIF-1α. In addition, the
function of CAD is also limited by the FIH oxygen sensor under
aerobic conditions. This double-locking system ensures the oxygen-
dependent regulation of CAD, and if so, NAD should be also dou-
ble-locked under aerobic conditions. Yet, little is known about the
oxygen-dependent regulation of NAD. Regarding this point, we con-
sidered that the oxygen-dependent targeting of NAD by PHDs and
pVHL provides a hint, and thus, we tested the possibility that
PHDs and pVHL participate in the regulation of NAD activity. We
found that Gal4-NAD activity was enhanced after either hypoxic or
desferrioxamine treatment. More interestingly, NAD activity wasB
D
ls were co-transfected with HA-HIF-1α, HA-HIF-1α△NAD (lacking aa. 513–595) or HA-
cells were incubated under hypoxic conditions for 8 h. Cell extracts were immunopre-
d using anti-VP16. (C) HEK293T cells were co-transfected with Gal4-NAD, VP16-CH1/
munoprecipitated with anti-Gal4, and coprecipitated VP16-CH1/CH3 were analyzed
ted under hypoxia conditions for 8 h. Protein interactions were identiﬁed by immuno-
AB
Fig. 6. CITED2 inactivates NAD by blocking the CH1–NAD interaction. Protein interac-
tions were checked using the mammalian two-hybrid assay. (A) HEK293T cells were
transfected with indicated plasmids and incubated under hypoxia for 16 h. Results
(means±SDs, n=6) are presented as relative luciferase activities versus the normoxic
controls. * and # denote pb0.05 versus the normoxic and hypoxic controls, respective-
ly. (B) Transfected HEK293T cells were stabilized for 24 h and incubated under nor-
moxic or hypoxic conditions for 16 h. Luciferase activities (means±SDs, n=4) were
normalized to β-gal activities and presented as relative values versus the normoxic
activity of wild-type Gal4-NAD. * and NS denote pb0.05 and pN0.05 between indicated
groups, respectively.
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was facilitated by VHL knock-down (Fig. 7.B). These ﬁndings suggest
that pVHL negatively regulates the function of NAD. Next, we
checked whether the Pro564 hydroxylation is required for the
pVHL inhibition of NAD. The activity of NAD_P564A mutant was
neither enhanced by hypoxia or desferrioxamine treatment, nor
affected by pVHL expression (Fig. 7.C, D). We also conﬁrmed that
Gal4-NAD and Gal4-NAD P564A expressions were not affected by
pVHL expression (Fig. S6). These results suggest that the pVHL
action depends on the PHD-mediated hydroxylation of Pro564.
3.8. pVHL interferes with the NAD–CH3 interaction
To understand how pVHL controls NAD activity, we investigated
the interactions among NAD, p300, and pVHL. NAD interacted with
p300 in VHL knocked-down cells even during normoxia, while it did
not in control cells (Fig. 8.A). Also, since Pro564 might be hydroxylat-
ed under normoxia regardless of VHL expression, Pro564 hydroxyl-
ation per se is unlikely to determine the NAD–p300 interaction.
Under hypoxia, NAD interacted with p300, but this interaction was
disrupted by pVHL (Fig. 8.B). Then, does pVHL compete for NAD bind-
ing with CH1 or CH3? When co-transfected with CHs, pVHL did not
affect the NAD–CH1 interaction (Fig. 8.C), but pVHL noticeably
reduced the NAD–CH3 interaction under hypoxia (Fig. 8.D). Toexamine whether pVHL interferes with the endogenous interaction
between HIF-1α and p300, we compared the HIF-1α–p300 binding
in VHL+/+ and VHL−/− RCC4 cells under normoxic conditions.
When endogenous HIF-1α was stabilized by MG132 (a proteasome in-
hibitor), p300 binding to HIF-1α was identiﬁed to be substantially en-
hanced in VHL−/− cells (Fig. 8.E). These results suggest that pVHL
blocks the NAD–CH3 interaction by preoccupying NAD and by so doing
controls NAD-dependent transcription in an oxygen-dependent fashion.
3.9. Proposed mechanism underlying the regulation of HIF-1α activity
On the CAD-dependent genes, p300 interacts with CAD through its
CH1 domain and facilitates the CAD-driven transcription. In nor-
moxia, CAD is hydroxylated at Asn803 by FIH and this modiﬁcation
prevents p300 binding to CAD. In hypoxia, CITED2 is induced and se-
questers p300 by binding its CH1 domain, leading to a feedback inhi-
bition of CAD activity. On the NAD-dependent genes, p300 interacts
with NAD through its CH1 and CH3 domains and transactivates the
genes. In normoxia, NAD is hydroxylated at Pro564 by PHDs and
recruits pVHL, which interferes with the CH3 binding to NAD. In
hypoxia, CITED2 inhibits the CH1 binding to NAD. Accordingly, HIF-
1α activity appears to be ﬁne-tuned by the molecular interplay that
controls p300 recruitment by NAD and by CAD (Fig. 9).
4. Discussion
Since NAD and CAD express different sets of hypoxia-induced
genes, they are believed to play different roles in cellular adaptation
to hypoxia. p300/CBP binding to HIF-1α is a critical step in hypoxic
gene expression. Therefore, molecules determining this interaction
are regarded as potential targets for the control of HIF-related dis-
eases. However, in contrast to CAD, it has not been determined how
NAD is regulated, and we addressed this point in the present study.
We found that NAD interacts with p300, and that it is activated during
hypoxia. In addition, we examined if CITED2 (previously known as an
inhibitor of CAD) also inhibits NAD. We found that CITED2 represses
NAD function by competing with NAD for p300 binding. Accordingly,
the present study provides a better understanding of gene expression
determined by HIF-1, and offers a potential strategy to control HIF-1
functionally by inhibiting the p300/CBP interaction.
p300 (like CBP) interacts with numerous transcription factors and
functions as a coactivator to facilitate gene expression [19,20]. p300
contains NR, CH1, KIX, Bromo, CH2, HAT, CH3, and Q-rich domains
[21], and of these, the CH1–3 domains provide interacting sites for
transcription factors and have distinct binding partners. As was men-
tioned above, CH1 is known to bind to CAD and CITED2 speciﬁcally
[14]. Furthermore, in the present study, NAD was found to interact
with CH1 and with CH3. Since NAD–p300 binding was dissociated
by the expression of either CH1 or CH3 peptide, CH1 and CH3 co-
binding might be required for the NAD–p300 association. Given
that Ets, p53, and Skip2 bind to both CH1 and CH3 [19,22,23], NAD
binding to both regions is not surprising. However, our ﬁndings con-
tradict a recent report. Ruas et al. carried out immunoprecipitation
and ﬂuorescence resonance energy transfer (FRET) analyses, and
found that NAD interacts with CH3 of CBP [11]. According to the
results obtained, CH1 also interacted with NAD, although this inter-
action was relatively weak as compared with the CH3 interaction.
However, in this previous study, CH domains of CBP and mouse
HIF-1α were used, whereas we used CH domains of p300 and
human HIF-1α constructs. Accordingly, we believe that these differ-
ences between plasmids might have been responsible for the result
differences.
In addition to protein stabilization, the activation of HIF-1α is crit-
ical for hypoxic signaling. It is well known that CAD activity is regulat-
ed oxygen-dependently through the FIH-mediated hydroxylation of
Asn803 [24], and in this previous study, it was shown that NAD
A B
C D
Fig. 7. pVHL controls NAD activity. HEK293T cells, which had been transfected with Gal4- wild-type NAD (A–B) or -mutated NAD (C–D) and indicated plasmids or siRNAs, were
incubated under hypoxia or with 130 μM DFO for 16 h. Luciferase activities (means±SDs, n=4) were normalized to β-gal activities and presented as relative values versus the
normoxic activity. * and NS denote pb0.05 and pN0.05 between two groups, respectively.
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domain degradable by oxygen, the stabilization of this domain
has been regarded to contribute to the hypoxic activation of NAD.
This means that no speciﬁc mechanism other than protein stabiliza-
tion has been considered in terms of understanding the hypoxic
activation of NAD. In the present study, despite no substantial change
in Gal4-NAD level, Gal4-NAD activity was signiﬁcantly enhanced
under hypoxic conditions. Furthermore, the interaction between
Gal4-NAD and p300 was enhanced by hypoxia and by desferrioxa-
mine. Accordingly, CAD and NAD both are likely to be functionally
regulated along oxygen tension.
Given that HIF-1α regulates the transcriptions of key tumor-pro-
moting factors, HIF-1α is generally regarded as one of the most com-
pelling targets for cancer therapy [25,26]. Indeed, many lines of
clinical and experimental evidence support the critical roles played
by HIF-1α in tumor promotion and metastasis [27]. In addition, it
has been reported that the anti-angiogenic effects of many anticancer
drugs are attributable to HIF-1α inhibition [28] and that HIF-1α in-
hibitors have anticancer effects in cultured cells and in vivo [26].
Here, we focused on the inhibitory role of CITED2 in HIF-1-driven
gene expression. These observations and ﬁndings beg the question
as to whether CITED2 is a possible target for cancer therapy, and a
few authors have suggested this possibility. For example, proteasome
inhibitors, which are emerging anticancer agents, stabilize CITED2
and by so doing block the hypoxic activation of HIF-1α, which may
be associated with the anti-angiogenic effects of these inhibitors
[17,29]. In addition, CITED2 level has been reported to be negatively
related to colon cancer cell invasiveness and with poor outcomes in
breast cancer [30,31]. Thus, CITED2 could be a marker of good prog-
nosis in some cancer patients, and its activation provides a potentialstrategy for cancer therapy. However, this putative role of CITED2
cannot be established by other than well-designed, large-scale clini-
cal studies.
In terms of the regulation of NAD, a previous report demonstrated
that PHD2 participates in its inhibitory regulation and in the degrada-
tion of HIF-1α [16]. NAD activity was enhanced during hypoxia re-
gardless of protein stabilization, but this hypoxic activation was not
shown by P564A and L573S NAD mutants. Furthermore, the NAD-
dependent gene PGK1 was up-regulated in PHD2 knocked-down
cells. Although prolyl-hydroxylation was identiﬁed to be involved in
functional regulation of NAD, the mechanism underlying the oxy-
gen-dependent regulation of NAD was not determined. In particular,
the role of p300/CBP in NAD regulation was not addressed. Neverthe-
less, this previously report provides a hint that the PHD-pVHL axis
might be involved in NAD regulation, and the present study demon-
strates interplay between NAD, pVHL, and p300.
Summarizing, we found that p300 interacts with two activation
domains of HIF-1α and subsequently facilitates the gene expressions
driven by these two domains. CITED2 snatches p300 from these two
domains by binding to CH1 of p300, which leads to the downregula-
tion of gene subsets activated differentially by the two domains. In
terms of its binding with p300, NAD differs from CAD; that is, CH1
and CH3 both are required for the p300–NAD interaction, whereas
CH1 alone is sufﬁcient for the p300–CAD interaction. We believe
that these results provide a deeper understanding of the molecular
mechanism underlying NAD-driven gene expression and of the
means by which CITED2 controls the transcriptions of HIF-1α target
genes.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.bbamcr.2011.08.018.
A B
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Fig. 8. pVHL interferes with CH3 binding to NAD. (A–B) HEK293T cells, which had been transfected as indicated, were incubated under normoxia for 8 h. Cell extracts were immu-
noprecipitated with anti-HA beads, and coprecipitated proteins were analyzed by immunoblotting. (C–D) Transfected HEK293T cells were incubated under hypoxia for 8 h, and
prepared for immunoprecipitation and immunoblotting with indicated antibodies. (E) VHL+/+ and VHL−/− RCC4 cells were incubated under normoxic conditions in the absence
(left panel) or the presence (right panel) of 10 μM MG132 for 8 h. HIF-1α was immunoprecipitated from lysates by being treated sequentially with anti-HIF-1α and proteinA/G
beads, and precipitated proteins were analyzed by immunoblotting.
Fig. 9. Proposed model for the regulation of HIF-1α activity. 1α, HIF-1α; 1β, HIF-1β;
NAD, N-terminal TAD; CAD, C-terminal TAD.
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